Pharmacy Groups tell HHS that Any Action on Rebate Rule Must Involve Fixing Pharmacy DIR Fees

WASHINGTON, DC – June 29, 2020 – NASP submitted a letter to HHS by NASP and the country’s leading pharmacy groups stating that any action on a prescription drug rebate rule must address skyrocketing fees extracted by some pharmacy benefit managers on behalf of plan sponsors in Medicare Part D.

Click here to read NASP’s letter to HHS